Dublin, July 04, 2018 (GLOBE NEWSWIRE) -- The "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.
This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million.
The report profiles 24 companies including many key and niche players such as:
- Bharat Serums and Vaccines Limited (India)
- Biotest AG (Germany)
- China Biologic Products, Inc. (China)
- Guizhou Taibang Biological Products Co., Ltd (China)
- CSL Limited (Australia)
- Grifols, S.A. (Spain)
- Hualan Biological Engineering Inc. (China)
- Kedrion S.p.A. (Italy)
- LFB Group (France)
- Octapharma AG (Switzerland)
- Shanghai RAAS Blood Products Co., Ltd. (China)
- Shire plc (Ireland)
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)
Key Topics Covered
1. INDUSTRY OVERVIEW
Immunoglobulins to See Steady Growth
Intravenous Immunoglobulin
A Proliferating Biologic
Application Areas
A Brief Review
Market Outlook
Competitive Scenario
2. MARKET TRENDS
Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins
Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
IVIg
The Mainstay of PI Therapy
Subcutaneous IG Formulations Gain Therapeutic Foothold
Hyperimmune Globulin
Taking IVIg Therapy a Step Ahead
Unsuccessful Clinical Trials for Alzheimer's
A major Setback for IVIg Market
Synthetic Replacements to IVIg Therapy
IVIg Therapy
Home-based vs. Outpatient Settings
Per Capita Consumption Rate Varies Across Countries
Favorable Reimbursement and High Usage make US the Largest Consumer
Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
Aging Global Population: Major Opportunity Indicator
Improving Healthcare Expenditure to Foster Growth
3. PLASMA PROTEINS - AN OVERVIEW
Plasma and Plasma Derivatives Continue to Dominate Blood Components Market
Regulations Exercise a Tight Rein over Plasma Therapy & Immunoglobulins
4. THERAPY OVERVIEW
5. RECENT INDUSTRY ACTIVITY
LFB Group's 10% IVIg Gains More Approvals in Europe
CSL Acquires Majority Stake in Ruide
Baxter Acquires Claris Injectables
ADMA Biologics Takes Over BTBU
Green Cross Receives FDA Complete Response Letter for IVIG-SN
China Biologic Products Completes Acquisition of Guizhou Taibang
ProMetic Completes Patient Enrolment for Phase III Pivotal IVIG Trial
Kroger Combines Axium Pharmacy and Modern HC
Shire Acquires Baxalta
FDA Accepts BLA for IVIG-SN from Green Cross
Kedrion Bags US Commercial Rights to BIVIGAM
China Biologic Products to Commence Clinical Trials on Next- Gen IVIG Products
FDA Clears ProMetic's IND for IVIg
LFB Obtains Initial Market Authorizations for 10% Liquid IVIg in Europe
Baxter Divests its BioScience Division
Emergent BioSolutions Acquires Cangene
CMS Begins Evaluation of Payment for In-home IVIG Administration
6. FOCUS ON SELECT PLAYERS
Bharat Serums and Vaccines Limited (India)
Biotest AG (Germany)
China Biologic Products, Inc. (China)
Guizhou Taibang Biological Products Co., Ltd (China)
CSL Limited (Australia)
Grifols, S.A. (Spain)
Hualan Biological Engineering Inc. (China)
Kedrion S.p.A. (Italy)
LFB Group (France)
Octapharma AG (Switzerland)
Shanghai RAAS Blood Products Co., Ltd. (China)
Shire plc (Ireland)
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)
7. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 24 (including Divisions/Subsidiaries 32)
- The United States (11)
- Canada (2)
- Japan (1)
- Europe (8)
- France (1)
- Germany (1)
- The United Kingdom (2)
- Italy (1)
- Spain (1)
- Rest of Europe (2)
- Asia-Pacific (Excluding Japan) (9)
- Latin America (1)
For more information about this report visit https://www.researchandmarkets.com/research/b4r2vx/global?w=12